The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Neuland Laboratories's Revenue for the
three
months ended in Mar. 2026 was ₹7,763 Mil. Neuland Laboratories's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹5,414 Mil.
Hence, Neuland Laboratories's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Neuland Laboratories Receivables Turnover Related Terms
Neuland Laboratories Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEULANDLAB vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a Receivables Turnover of 1.43 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neuland Laboratories and its competitors. According to the industry distribution chart, Neuland Laboratories ranks #520 out of 947 companies in the Drug Manufacturers industry, placing it in the top 54.9%.
Is Neuland Laboratories' Receivables Turnover too high?
Neuland Laboratories' current Receivables Turnover is 1.43. The Drug Manufacturers industry median Receivables Turnover is 5.07. Neuland Laboratories' value of 1.43 is 71.8% below this industry median. Based on the distribution chart, Neuland Laboratories ranks #520 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #520 out of 947 companies for Receivables Turnover. This places Neuland Laboratories in the lower half of its industry. The industry median Receivables Turnover is 5.07. Neuland Laboratories' value of 1.43 is 71.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Receivables Turnover of 1.43 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Receivables Turnover is 1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,036.83, compared to a current price of ₹19,506.00 — trading 21.6% above its estimated fair value. The current Receivables Turnover is 1.43 and 71.8% below the Drug Manufacturers industry median of 5.07. Neuland Laboratories' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Receivables Turnover is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹19,506.00 is trading 21.6% above its estimated GF Value™ of ₹16,036.83.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Receivables Turnover: 1.43
GF Value™: ₹16,036.83 vs. price of ₹19,506.00 (21.6% above fair value)
Industry Position: 71.8% below the Drug Manufacturers median (#520 of 947)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
